Home/Filings/4/0001209191-21-065716
4//SEC Filing

COLELLA SAMUEL D 4

Accession 0001209191-21-065716

CIK 0001419600other

Filed

Nov 18, 7:00 PM ET

Accepted

Nov 19, 10:12 AM ET

Size

41.6 KB

Accession

0001209191-21-065716

Insider Transaction Report

Form 4
Period: 2021-11-19
COLELLA SAMUEL D
Director10% Owner
Transactions
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-199,0000 total
    Exercise: $17.61Exp: 2024-03-02Common Stock (9,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-1912,5000 total
    Exercise: $13.83Exp: 2026-06-09Common Stock (12,500 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-1912,5000 total
    Exercise: $28.14Exp: 2028-06-19Common Stock (12,500 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-1912,5000 total
    Exercise: $11.74Exp: 2029-06-18Common Stock (12,500 underlying)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh9,000$76,5000 total
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh19,653$167,0510 total(indirect: By Colella Partners II)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh1,000$8,5000 total(indirect: By Trust)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh72,035$612,2980 total(indirect: By Trust)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh5,000$42,5000 total(indirect: By Trust)
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-1912,5000 total
    Exercise: $20.16Exp: 2027-06-21Common Stock (12,500 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-197,0000 total
    Exercise: $9.22Exp: 2031-06-23Common Stock (7,000 underlying)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh5,871$49,9040 total(indirect: By Versant Side Fund III)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh250$2,1250 total(indirect: By Spouse)
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-199,0000 total
    Exercise: $21.85Exp: 2025-06-16Common Stock (9,000 underlying)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh994,129$8,450,0970 total(indirect: By Versant Venture Capital III L.P.)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh388,683$3,303,8060 total(indirect: By LLC)
  • Disposition to Issuer

    Common Stock

    2021-11-19$8.50/sh943$8,0160 total(indirect: By Colella Partners)
  • Disposition to Issuer

    Stock option (right to buy)

    2021-11-197,0000 total
    Exercise: $11.88Exp: 2030-06-09Common Stock (7,000 underlying)
Footnotes (11)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
  • [F10]Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II.
  • [F11]At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
  • [F2]At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
  • [F3]2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92.
  • [F4]The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust.
  • [F5]The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust.
  • [F6]The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
  • [F7]The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
  • [F8]The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
  • [F9]Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners.

Issuer

Flexion Therapeutics Inc

CIK 0001419600

Entity typeother

Related Parties

1
  • filerCIK 0001201580

Filing Metadata

Form type
4
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 10:12 AM ET
Size
41.6 KB